Rivoceranib

Generic Name
Rivoceranib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C24H23N5O
CAS Number
811803-05-1
Unique Ingredient Identifier
5S371K6132
Background

Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).

Indication

本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Apatinib Dose Titration in Advanced or Metastatic Gastric Cancer

Not Applicable
Completed
Conditions
Gastric Cancer
Interventions
Drug: Apatinib
First Posted Date
2016-05-06
Last Posted Date
2022-03-11
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
60
Registration Number
NCT02764268
Locations
🇨🇳

Shanghai 6th People's Hospital, Shanghai, Shanghai, China

The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer

First Posted Date
2016-04-11
Last Posted Date
2016-04-12
Lead Sponsor
Third Military Medical University
Target Recruit Count
25
Registration Number
NCT02733107
Locations
🇨🇳

Daping Hospital, Third Military Medical University, Chongqing, Chongqing, China

Study of Apatinib in Patients With Differentiated Thyroid Cancer

Phase 2
Completed
Conditions
Thyroid Cancer
Interventions
Drug: Apatinib
First Posted Date
2016-04-07
Last Posted Date
2022-01-20
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
20
Registration Number
NCT02731352
Locations
🇨🇳

Peking Union Medical College Hospital, Peking, China

A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients

Phase 1
Conditions
Hepatocellular Carcinoma
Interventions
Drug: Apatinib
First Posted Date
2016-04-04
Last Posted Date
2016-04-04
Lead Sponsor
Peking University Cancer Hospital & Institute
Target Recruit Count
30
Registration Number
NCT02727309
Locations
🇨🇳

Department of Interventional Therapy, Beijing, Beijing, China

Apatinib as Second-line Treatment of Advanced Pancreatic Cancer

Phase 2
Conditions
Pancreatic Neoplasms
Interventions
Drug: Apatinib
First Posted Date
2016-04-04
Last Posted Date
2016-12-02
Lead Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Target Recruit Count
30
Registration Number
NCT02726854
Locations
🇨🇳

First affiliate hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China

Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy

Phase 2
Completed
Conditions
Osteosarcoma
Metastasis
Interventions
Drug: apatinib
First Posted Date
2016-03-17
Last Posted Date
2018-04-23
Lead Sponsor
GUO WEI
Target Recruit Count
37
Registration Number
NCT02711007
Locations
🇨🇳

Peking University People's Hospital, Beijing, Beijing, China

Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma

First Posted Date
2016-03-10
Last Posted Date
2016-03-10
Lead Sponsor
First Affiliated Hospital of Kunming Medical University
Target Recruit Count
60
Registration Number
NCT02704767

Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study

First Posted Date
2016-03-08
Last Posted Date
2016-03-08
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
40
Registration Number
NCT02702323

Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer

First Posted Date
2016-03-03
Last Posted Date
2018-10-17
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
20
Registration Number
NCT02697838
Locations
🇨🇳

Rongbo Lin, Fuzhou, Fujian, China

Study of Apatinib in Metastatic Esophageal Cancer

Phase 2
Conditions
Esophageal Cancer
Interventions
Drug: Apatinib
First Posted Date
2016-02-17
Last Posted Date
2016-02-17
Lead Sponsor
Huai'an First People's Hospital
Target Recruit Count
40
Registration Number
NCT02683655
Locations
🇨🇳

Huaian First People's Hospital, Huaian, Jiangsu, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy